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Dmitri Sviridov1, John Blangero4, Jeremy B. M. Jowett1†, and Kiymet Bozaoglu1,2,7*
1Baker IDI Heart and Diabetes Institute, 75 Commercial Road, Melbourne, VIC 3004, Australia; 2Murdoch Children’s Research Institute, 50 Flemington Road, Parkville, VIC 3052,
Australia; 3Department of Pathology, University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia; 4South Texas Diabetes and Obesity Institute, University of Texas
Rio Grande Valley School of Medicine, One West University Blvd. Brownsville, Texas 78520, USA; 5University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009,
Australia; 6Curtin University, Kent St, Bentley, WA 6102, Australia; and 7Department of Paediatrics, University of Melbourne, 50 Flemington Road, Parkville,VIC 3052, Australia
Received 19 May 2016; revised 26 November 2016; editorial decision 27 April 2017; accepted 25 May 2017; online publish-ahead-of-print 26 June 2017
See page 3588 for the editorial comment on this article (doi: 10.1093/eurheartj/ehx506)
Aims The recent failures of HDL-raising therapies have underscored our incomplete understanding of HDL biology.
Therefore there is an urgent need to comprehensively investigate HDL metabolism to enable the development of
effective HDL-centric therapies. To identify novel regulators of HDL metabolism, we performed a joint analysis of
human genetic, transcriptomic, and plasma HDL-cholesterol (HDL-C) concentration data and identified a novel
association between trafficking protein, kinesin binding 2 (TRAK2) and HDL-C concentration. Here we characterize




Analysis of lymphocyte transcriptomic data together with plasma HDL from the San Antonio Family Heart Study
(n = 1240) revealed a significant negative correlation between TRAK2 mRNA levels and HDL-C concentration,
HDL particle diameter and HDL subspecies heterogeneity. TRAK2 siRNA-mediated knockdown significantly
increased cholesterol efflux to apolipoprotein A-I and isolated HDL from human macrophage (THP-1) and liver
(HepG2) cells by increasing the mRNA and protein expression of the cholesterol transporter ATP-binding cassette,
sub-family A member 1 (ABCA1). The effect of TRAK2 knockdown on cholesterol efflux was abolished in the
absence of ABCA1, indicating that TRAK2 functions in an ABCA1-dependent efflux pathway. TRAK2 knockdown
significantly increased liver X receptor (LXR) binding at the ABCA1 promoter, establishing TRAK2 as a regulator of
LXR-mediated transcription of ABCA1.
...................................................................................................................................................................................................
Conclusion We show, for the first time, that TRAK2 is a novel regulator of LXR-mediated ABCA1 expression, cholesterol
efflux, and HDL biogenesis. TRAK2 may therefore be an important target in the development of anti-
atherosclerotic therapies.
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Translational Perspective
Our work identifies TRAK2 as a novel regulator of HDL metabolism and cholesterol efflux. TRAK2 may be an important
target in the development of anti-atherosclerotic therapies.
* Corresponding author. Tel: þ613 9936 6563, Fax: þ613 8341 6390, Email: kiymet.bozaoglu@mcri.edu.au
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Studies into the regulation of HDL-cholesterol (HDL-C) levels have
revealed that HDL metabolism is complex, and involving multiple path-
ways. The process of HDL biogenesis is mediated primarily by the liver
and involves the secretion of apoA-I which stimulates cholesterol
efflux through the ABCA1 cholesterol transporter.1 While cholesterol
efflux is integral to HDL biogenesis, it also enables removal of excess
cholesterol from macrophages towards preventing development of
atherosclerotic lesions.2 The movement of cholesterol from peripheral
tissues to the liver for clearance is termed reverse cholesterol trans-
port (RCT), a pathway that represents a key atheroprotective function
of HDL.3 The liver X receptors (LXRs) are transcription factors that
play a key role in regulation of RCT.4 LXRs function as cholesterol sen-
sors, and when cellular cholesterol content is high they activate the
transcription of genes involved in cholesterol efflux, including ABCA1
and ABCG1, to promote RCT.5,6
The well-established inverse correlation between HDL-C concen-
tration and cardiovascular disease (CVD) led to development of the
‘HDL hypothesis’ which postulates that therapeutic elevation of HDL
levels can reduce CVD risk.7 The pursuit of efficacious HDL-centric
therapy has proved difficult, with pharmacological attempts at raising
HDL-C levels failing to reduce the incidence of cardiovascular events.8
These results highlight that our current understanding of HDL metabo-
lism is incomplete. In parallel, interest in pharmacological enhancement
of other atheroprotective aspects of HDL biology has emerged, with
particular attention on those that promote the role of HDL in RCT.1,9
Therefore consolidation of the mechanistic basis of cholesterol efflux,
HDL biogenesis, and broader HDL metabolism is required for the
development of a successful HDL-centric therapy.
To identify novel regulators of HDL metabolism, we utilized an
innovative approach of integrating large-scale human transcriptomic
and genome-wide association (GWA) data to identify genes demon-
strating a novel association with plasma HDL-C concentration.10
Since a relationship with HDL-C concentration may reflect an effect
on aspects of HDL biology including biogenesis and cholesterol
efflux, this approach was anticipated to reveal targets that may also
influence other HDL metrics of pharmacological interest. Our analy-
sis identified a novel significant in vivo association between trafficking
protein, kinesin binding 2 (TRAK2), and plasma HDL-C concentration,
thereby establishing TRAK2 as a candidate gene for further investiga-
tion.10 TRAK2 is a regulator of protein and organelle trafficking
through its role as a kinesin and dynein binding protein, with its func-
tion in neuronal mitochondrial trafficking most thoroughly
characterized.11,12 As a role for TRAK2 in HDL or cholesterol
metabolism had not been previously characterized, functional studies
were undertaken to validate this novel association.
Here we provide data to establish a role for TRAK2 in HDL
metabolism, demonstrating a negative in vivo correlation between
TRAK2 mRNA expression and HDL-C concentration, HDL diameter,
and HDL subspecies heterogeneity. For the first time, we provide
functional evidence of the mechanism underlying the association
between TRAK2 and HDL-C, revealing that TRAK2 siRNA knock-
down significantly promotes cholesterol efflux from human macro-
phage and liver cells by increasing LXR-mediated transcription of
ABCA1. These data identify TRAK2 as an important contributor to
HDL metabolism and function.
Methods
Detailed methods are available in the Supplementary material online.
Participants from the San Antonio Family Heart Study (SAFHS)
(n 1400), all provided informed consent and recruitment, lymphocyte
isolation, and statistical analyses of genetic and transcriptomic data (avail-
able for 1240 participants) are previously described.13 Separation of lipo-
protein subfractions, and lipoprotein diameter, was determined by
gradient gel electrophoresis.
Cellular investigations were performed on human Hepatocellular
Carcinoma Cells (HepG2), Intestinal cells (FHs74Int), and Monocytes
(THP-1) differentiated into macrophages. Knockdown of TRAK2 and
ABCA1 gene expression in these cell lines was achieved following transfec-
tion with siRNA. Gene expression was analysed by real-time polymerase
chain reaction, and calculated using the comparative Ct method with nor-
malization to the housekeeping gene ACTB. Protein levels were measured
using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting.
Cholesterol efflux was measured following a 2-h incubation with apoA-I
(30 mg/ml) or HDL particles isolated from human plasma (40 mg/ml).
Measurement of LXR-a binding in the ABCA1 promoter region was
determined by chromatin immunoprecipitation (ChIP) assay. Significance
was calculated using the 2-sided Student’s t-test and Stouffer’s Z-score
method where a P < 0.05 was considered significant.
Results
TRAK2 mRNA expression is negatively
correlated with human plasma
HDL-cholesterol concentration, HDL
particle diameter, and HDL
subpopulation heterogeneity
We previously identified that TRAK2 mRNA expression was signifi-
cantly associated with human plasma HDL-C concentration,10 how-
ever the nature of this association was unknown. Therefore we
performed further analyses of the SAFHS gene expression data and
identified a significant and negative correlation between TRAK2
expression and plasma HDL-C concentration after adjustment for
multiple covariates including age and sex (b = -0.11, P = 1.15 10-4).
This significant association was largely genetic in origin (genetic
correlation = -0.34, P = 4.5 10-4). Examination of TRAK2 sequence
data available from the SAFHS cohort to search for cis-acting variants
influencing TRAK2 expression identified two variants that were signifi-
cantly associated with TRAK2 mRNA levels and plasma HDL-C con-
centration (see Supplementary material online, Table S3, P = 0.0062
and P = 0.013), supporting the genetic basis of the association
between TRAK2 and HDL-C concentration. Examination of the tissue
distribution of TRAK2 in humans using publically available data from
the Genotype-Tissue Expression project revealed that TRAK2 was
most highly expressed in the brain, heart, arteries and thyroid (see
Supplementary material online, Figure S1A).14 In mice, across the
selected tissues examined Trak2 was most highly expressed in the
spleen, bone marrow-derived macrophages and liver (see
Supplementary material online, Figure S1B). Among human cell lines
derived from tissues relevant to HDL-C metabolism, TRAK2 was
most highly expressed in hepatic cells (see Supplementary material
online, Figure S1C).
























































































Gradient gel electrophoresis studies on SAFHS plasma samples
revealed a significant negative correlation between TRAK2 expression
and HDL particle diameter [excluding HDL1 b = -0.10 standard devia-
tion units (SDU), P = 7.2 10-4; including HDL1 b = -0.10 SDU,
P = 7.6 10-4] (Table 1). HDL particles are heterogeneous and can be
separated into subpopulations by particle size (HDL2b, -2a, -3a, -3b, -
3c).15 Fractionation of HDL subpopulations from SAFHS participants
revealed that TRAK2 expression was significantly correlated with the
level of HDL2b (b = -0.11 SDU, P = 2.8 10-4), HDL3a (b = 0.08
SDU, P = 0.012) and HDL3b (b = -0.11 SDU, P = 1.6 10-4) particles
(Table 1). Overall, these data reveal that TRAK2 expression is signifi-
cantly correlated with multiple HDL parameters in humans, and that
genetic variation influencing TRAK2 expression may also contribute to
the regulation of HDL-C concentration.
TRAK2 mediates cholesterol efflux to
apoA-I and HDL in human macrophage
cells
Cholesterol efflux from macrophages to HDL particles is an essential
part of RCT and represents a key atheroprotective function of HDL.2
We manipulated TRAK2 gene expression using siRNA-mediated
knockdown in human THP-1 human monocytes differentiated into
macrophages and measured cholesterol efflux. Targeted knockdown
of TRAK2 significantly reduced TRAK2 gene expression in THP-1
macrophage cells by up to 90% relative to non-targeting control
(NTGC) siRNA transfected cells (Figure 1A, P < 0.00001). TRAK2
knockdown significantly increased cholesterol efflux to apoA-I by
35% (Figure 1B, P = 0.039) and to isolated HDL by 20% (Figure 1B,
P = 0.0038) relative to cells transfected with NTGC siRNA. These
data validate our human in vivo data and suggest that conditions of
low-TRAK2 expression may promote RCT.
TRAK2 is a key regulator of hepatic
cholesterol efflux and HDL biogenesis
We then assessed whether TRAK2 was involved in the regulation of
HDL biogenesis, a process mediated by cholesterol efflux to apoA-I.1
Since the liver and intestine are the primary and secondary sites of
HDL biogenesis respectively, the effect of TRAK2 knockdown on
cholesterol efflux in human liver (HepG2) cells and human intestinal
(FHs74Int) cells was investigated. Transfection of TRAK2 siRNA
reduced TRAK2 gene expression in HepG2 and FHs74INT cells by
80% and 90%, respectively (Figure 1A, P < 0.00001). TRAK2 knock-
down in HepG2 cells significantly increased cholesterol efflux to
apoA-I by 60% (Figure 1B, P < 0.00001), but had no significant effect
on efflux to apoA-I in FHs74Int cells, relative to NTGC siRNA
(Figure 1B, P = 0.20), suggesting that TRAK2’s role in HDL biogenesis
is primarily hepatic. TRAK2 knockdown did not increase efflux in the
absence of a cholesterol acceptor (see Supplementary material
online, Figure S2, P = 0.80), indicating that the significant effect of
TRAK2 knockdown is not due to background passive cholesterol
efflux. Further investigation demonstrated that TRAK2 knockdown
significantly increased HDL production in HepG2 cells by 70%
(Figure 1C; P < 0.00001); and increased the mRNA expression of
APOA1 in HepG2 cells by 25% relative to NTGC siRNA (Figure 1D,
P = 0.0026). A non-significant trend to increase apoA-I protein levels
and secretion was additionally observed (see Supplementary material
online, Figure S3, P = 0.38 and P = 0.080, respectively), suggesting that
TRAK2 may have broader effects on HDL biogenesis.
Overexpression of TRAK2 using plasmid DNA showed a significant
increase in TRAK2 expression (see Supplementary material online,
Figure S4A, P = 0.0041), however only a modest albeit significant
decrease in cholesterol efflux was observed (see Supplementary
material online, Figure S4B, P = 0.029).
We then investigated the effect of TRAK2 knockdown on efflux to
isolated human HDL in HepG2 and FHs74Int cells. Although these
cell types are not typically recognized as endogenous promoters of
cholesterol efflux to HDL, it has been suggested that hepatic cells can
utilize this pathway to release unwanted cholesterol.16 We observed
a significant 40% increase in cholesterol efflux to isolated HDL in
HepG2 cells (Figure 1B, P = 0.0026), but TRAK2 knockdown had no
significant effect on efflux to isolated HDL in FHs74Int cells
(Figure 1B, P = 0.063), relative to NTGC siRNA. Overall, these results
reveal a novel role for TRAK2 in HDL metabolism, and specifically as
a novel regulator of cholesterol efflux and hepatic HDL biogenesis.
TRAK2 knockdown increases ABCA1
mRNA and protein expression levels
ABCA1 mediates cholesterol efflux to apoA-I and HDL, while
ABCG1 and SR-BI (encoded by SCARB1) only facilitate cholesterol
efflux to HDL.1 We therefore investigated whether these cholesterol
transporters were mediating the significant effect of TRAK2 knock-
down on cholesterol efflux. TRAK2 knockdown significantly
increased ABCA1 mRNA levels by 170% in HepG2 cells (Figure 2A,
P = 0.000036) and by 70% in THP-1 macrophage cells (Figure 2A,
P = 0.012) compared to controls, but had no significant effect on
ABCG1 expression (Figure 2A, P = 0.85 and P = 0.30, respectively).
TRAK2 knockdown modestly but significantly reduced SCARB1 gene
expression in HepG2 and THP-1 macrophage cells (Figure 2A,
P = 0.00056 and P = 0.013 respectively). Furthermore, we observed a
significant 80% increase in ABCA1 protein levels (Figure 2B, and C
P = 0.046), while there was no marked difference in ABCG1 or SR-BI
protein abundance (Figure 2B and C). Overexpression of TRAK2 had
no significant effect on ABCA1 expression (see Supplementary mate-
rial online, Figure S4C, P = 0.066). Taken together, these observations
suggest that TRAK2 knockdown increases cholesterol efflux to
.................................................................................................
Table 1 The association of TRAK2 mRNA with HDL




HDL diameter excluding HDL1 -0.101 0.00072a
HDL diameter including HDL1 -0.101 0.00076a
HDL1 (13.0–20.0 nm) -0.026 0.42
HDL2b (9.7–12.9 nm) -0.109 0.00028a
HDL2a (8.8–9.7 nm) -0.015 0.63
HDL3a (8.2–8.8 nm) 0.079 0.012a
HDL3b (7.8–8.2 nm) 0.113 0.00016a
HDL3c (7.2–7.8 nm) 0.055 0.072
The particle size range of each HDL fraction is described.
aTraits significantly correlated with TRAK2 mRNA (P < 0.05).





















..apoA-I and HDL by increasing the transcription and protein abun-
dance of ABCA1.
TRAK2’s effects on hepatic cholesterol
efflux and HDL biogenesis are dependent
on ABCA1
To investigate whether TRAK2 was regulating cholesterol efflux in an
ABCA1-dependent pathway, we performed siRNA-mediated double
knockdown of ABCA1 and TRAK2 to silence both genes simultane-
ously. A 75% suppression in ABCA1 gene expression relative to
NTGC siRNA was observed in HepG2 cells (Figure 3A,
P = 0.000078), mirrored by a strong knockdown at the protein level
(Figure 3B). Transfection of ABCA1 siRNA ablated cholesterol efflux
to apoA-I (Figure 3C, P < 0.00001), and significantly reduced efflux to
isolated HDL by 75% (Figure 3C, P < 0.00001). Cells transfected with
both ABCA1 and TRAK2 siRNA displayed ablated cholesterol efflux
relative to NTGC siRNA at levels comparable to cells transfected
only with ABCA1 siRNA (Figure 3C, P < 0.00001). These results pro-
vide evidence that TRAK2 knockdown cannot increase cholesterol
efflux in the absence of ABCA1. Knockdown of ABCA1 expression
had no significant effect on TRAK2 mRNA levels (Figure 3A), suggest-
ing that TRAK2 functions upstream of ABCA1 in this efflux pathway.
To further support that TRAK2 regulates an ABCA1-dependent
cholesterol efflux pathway, we treated HepG2 cells with ABCA1
inhibitor Cyclosporine A (CsA),17 and examined the effect on choles-
terol efflux. CsA treatment significantly reduced ABCA1 expression
by 75% relative to control (Figure 4A, P = 0.00023), ablated
Figure 1 TRAK2 siRNA-mediated knockdown induces cholesterol efflux and apoA-I expression. (A) siRNA-mediated gene knockdown signifi-
cantly decreased TRAK2 expression in hepatic HepG2, THP-1 macrophage, and FHs74INT intestinal cells relative to non-targeting control (NTGC)
siRNA; n = 4 independent experiments. (B) Cholesterol efflux to apoA-I and HDL was significantly increased following siRNA-mediated knockdown
of TRAK2 in HepG2 and THP-1 macrophage cells, relative to NTGC siRNA. Transfection of FHs74INT cells with TRAK2 siRNA did not significantly
affect cholesterol efflux; n = 3–4 independent experiments. (C) siRNA-mediated knockdown of TRAK2 significantly increased HDL production in
HepG2 cells relative to NTGC siRNA; n = 5 biological replicates. (D) TRAK2 knockdown significantly increased APOA1 mRNA expression relative to
NTGC siRNA in HepG2 cells; n = 5 independent experiments. Data are represented as the mean ± standard deviation of n.























..cholesterol efflux to apoA-I (Figure 4B, P < 0.00001), and suppressed
the effect of TRAK2 knockdown on cholesterol efflux (Figure 4B).
However, TRAK2 knockdown was able to modestly but significantly
increase cholesterol efflux during CsA treatment relative to the
NTGC siRNA (Figure 4B, P < 0.00001), which was reproducible with
a shorter treatment period (see Supplementary material online,
Figure S5, P = 0.0019). This increase in efflux correlated with a signifi-
cant increase in ABCA1 expression, where TRAK2 knockdown
approximately doubled ABCA1 mRNA expression relative to
NTGC siRNA during CsA treatment (Figure 4B, P = 0.0032). This sug-
gests that TRAK2 knockdown is able to increase ABCA1 levels even
in conditions of low-ABCA1 expression.
Given that cholesterol egress from late endosomes to the plasma
membrane is required for efficient ABCA1-mediated cholesterol
efflux,18 we used U18666A to inhibit cholesterol movement from
the late endosomal network and measured cholesterol efflux.
Treatment with U18666A suppressed the effect of TRAK2 knock-
down on cholesterol efflux (see Supplementary material online,
Figure S6A), consistent with the role of TRAK2 in an ABCA1-
dependent pathway. Interestingly, U18666A treatment doubled the
increase in ABCA1 expression elicited by TRAK2 knockdown relative
to transfected cells without treatment (see Supplementary material
online, Figure S6B, untreated cells P = 0.000046 and treated cells
P = 0.000048), suggesting that the effect of TRAK2 knockdown on
ABCA1 expression is influenced by cholesterol accumulation in the
late endosomal network. TRAK2 has been previously characterized
as a regulator of endosomal trafficking.19 We therefore utilized
immunofluorescence confocal microscopy to determine whether
TRAK2 knockdown also influenced the localization of early and late
endosomes in HepG2 cells, but no discernible changes in endosomal
Figure 2 The effect of TRAK2 on ABCA1, ABCG1, and SR-BI expression. (A) TRAK2 knockdown in HepG2 and THP-1 macrophage cells signifi-
cantly increased ABCA1 mRNA expression, significantly decreased SCARB1 mRNA levels, but had no significant effect on ABCG1 mRNA expression
levels relative to non-targeting control (NTGC) siRNA; n = 4. (B) siRNA-mediated knockdown of TRAK2 increased ABCA1 abundance but had no
marked effect on ABCG1 or SR-BI protein levels relative to NTGC siRNA in HepG2 cells. (C) TRAK2 knockdown significantly increased ABCA1
protein levels. There was no significant difference in ABCG1 or SR-BI protein expression; n = 2. Data are represented as the mean ± standard devia-
tion of n independent experiments.
























..organization was observed (see Supplementary material online,
Figure S7).
In summary, these data support that TRAK2 mediates its effect on
cholesterol efflux through regulating the expression of ABCA1.
TRAK2 knockdown increases LXR
binding to LXR response element
regions within the ABCA1 promoter
LXRs regulate ABCA1 expression by binding to LXR response ele-
ments (LXR-RE) within the promoter region where they mediate
activation and repression of transcription.20 LXR agonists promote
transcription by increasing LXR binding to the promoter and causing
the release of co-repressors.20,21 To determine if TRAK2 was regu-
lating ABCA1 expression by modulating LXR-mediated transcription
of ABCA1, we utilized a ChIP assay to evaluate LXR-a binding at four
LXR-RE regions within the ABCA1 promoter. Treatment of HepG2
cells with LXR agonist TO901317 significantly increased LXR-a bind-
ing at the ABCA1 promoter within Regions 2 and 3 by 150% (Figure 5,
P = 0.032 and P = 0.00025, respectively), consistent with their loca-
tion near the ABCA1 transcription start site. No LXR-a binding was
detectable at Region 1 within the 5’ region of intron 1, while a trend
to increase LXR-a binding was observed at Region 4 which was the
most 5’ distal sequence (see Supplementary material online, Figure S8,
P = 0.145). TRAK2 siRNA-mediated knockdown had a larger effect
on LXR-a binding than TO901317 alone, significantly increasing
LXR-a binding at the ABCA1 promoter within Regions 2 and 3 by
450% (Figure 5, P = 0.0496 and P = 0.038, respectively), while a non-
significant trend to increase LXR-a binding was observed at Region 4
(see Supplementary material online, Figure S8, P = 0.38). Interestingly,
treatment of cells transfected with TRAK2 siRNA with TO901317
abrogated the effect of TRAK2 knockdown on LXR-a binding, where
Figure 3 TRAK2’s effect on cholesterol efflux is dependent on ABCA1. (A) siRNA-mediated gene knockdown of ABCA1 significantly decreased
ABCA1 mRNA expression relative to non-targeting control (NTGC) siRNA in HepG2 cells. TRAK2 mRNA expression was not affected by knock-
down of ABCA1; n = 3. (B) siRNA-mediated knockdown of ABCA1 ablated protein expression in HepG2 cells. (C) TRAK2 siRNA treatment signifi-
cantly increased cholesterol efflux while transfection with ABCA1 siRNA, or with both TRAK2 and ABCA1 siRNA, ablated cholesterol efflux to
apoA-I and to HDL relative to NTGC siRNA in HepG2 cells; n = 3. Data are represented as the mean ± standard deviation of n independent
experiments.


















































an increase comparable to cells treated with TO901317 alone was
observed (Figure 5). The mRNA expression of LXRa and several
other transcription factors involved in activating or repressing ABCA1
transcription (RXRa, PPARa, SREBP2, and ZNF202)20 was examined
in cells transfected with siRNA, however TRAK2 knockdown had no
significant effect on the expression of these genes (see
Supplementary material online, Figure S9). Overall, these data indicate
that TRAK2 regulates ABCA1 expression and cholesterol efflux
through an effect on LXR-mediated transcription of ABCA1.
Discussion
Given the disappointing clinical trial outcomes for HDL-C raising
therapies,8 it is evident that our understanding of HDL metabolism is
incomplete. To address this, we utilized an innovative joint analysis of
human metabolic, GWA and transcriptomic data to identify novel
regulators of in vivo plasma HDL-C concentration, and reported
TRAK2 as a highly ranking candidate gene for further investigation.10
TRAK2 belongs to the TRAK protein family which are best
characterized as motor-adaptor proteins that link mitochondria to
microtubule-based motors kinesin and dynein.11,12 Since TRAK2 had
not been previously implicated in HDL or cholesterol metabolism,
the molecular basis of this association with HDL-C was unknown.
Here, for the first time, we demonstrate that TRAK2 is an important
contributor to the maintenance of HDL-C levels, HDL particle diam-
eter, and HDL subpopulation levels. We further characterize a bio-
logical role for TRAK2 as a regulator of macrophage cholesterol
efflux and hepatic HDL biogenesis, demonstrating that TRAK2
siRNA-mediated knockdown significantly increases LXR-a binding at
the ABCA1 promoter, ABCA1 expression, and cholesterol efflux
(Figure 6). Our data thereby validate our initial in silico approach for
identifying novel regulators of in vivo HDL metabolism, and further-
more demonstrates how GWA data can be effectively leveraged to
identify novel regulators of multifactorial traits and disorders.
Expanding on our earlier study,10 we have shown that TRAK2 is
significantly and negatively correlated with in vivo HDL-C and HDL
particle diameter, and provided additional evidence supporting a
Figure 4 The effect of Cyclosporine A (CsA) treatment on cholesterol efflux and ABCA1 gene expression. (A) ABCA1 mRNA expression was sig-
nificantly reduced in HepG2 cells treated with CsA relative to vehicle control. TRAK2 knockdown significantly increased the expression of ABCA1 in
cells treated with CsA relative to non-targeting control (NTGC) siRNA; n = 2. (B) CsA treatment suppressed cholesterol efflux to apoA-I in HepG2
cells transfected with NTGC siRNA. TRAK2 siRNA treatment significantly increased cholesterol efflux to apoA-I relative to NTGC siRNA; n = 3.
Data are represented as the mean ± standard deviation of n independent experiments.
Figure 5 TRAK2 siRNA-mediated knockdown increases LXR-a
binding to the ABCA1 promoter in HepG2 cells. TO901317 treat-
ment and siRNA-mediated knockdown of TRAK2 treatment signifi-
cantly increased LXR-a binding to LXR-a response element regions
within the ABCA1 promoter relative to control. Treatment with
TO901317 diminished the effect of TRAK2 knockdown. Data are
represented as the mean ± standard deviation of three independent
experiments.

















































..genetic association between TRAK2 and plasma HDL-C concentra-
tion. Fractionation of the major HDL subpopulations further revealed
a significant negative correlation between TRAK2 expression and the
abundance of larger HDL2b particles, while a significant positive cor-
relation with smaller HDL3a and HDL3b species was observed. The
basis of the shift towards increased HDL2b and decreased HDL3a
and HDL3b particle abundance in conditions of low-TRAK2 expres-
sion is unclear, though it is consistent with recent observations of a
slower clearance rate of large HDL2b particles and a faster clearance
of small HDL3a and HDL3b particles in a setting of high HDL-C lev-
els.22 TRAK2’s role in in vivo HDL homeostasis is therefore broader
than an association with HDL-C concentration.
We have demonstrated that TRAK2 siRNA knockdown signifi-
cantly promotes cholesterol efflux from human macrophage and liver
cells. The capacity of TRAK2 knockdown to significantly increase
cholesterol efflux and HDL production in vitro is consistent with the
observed negative in vivo correlation between TRAK2 mRNA and
human plasma HDL-C concentration and HDL particle diameter.
The absence of an effect of TRAK2 knockdown on cholesterol efflux
in human intestinal FHs74Int cells does not contradict the in vivo asso-
ciation between TRAK2 and HDL-C abundance, but rather indicates
that TRAK2’s role in HDL biogenesis is specifically hepatic. Our data
therefore signify the role of TRAK2 in HDL biogenesis, given the liver
produces the majority of plasma HDL particles.23 Evidence of
increased apoA-I expression in HepG2 cells transfected with TRAK2
siRNA suggests that TRAK2’s role in hepatic HDL biogenesis may be
multifaceted.
While cholesterol efflux from macrophages may not significantly
contribute to total HDL-C levels,24 it is an important atheroprotec-
tive function of HDL.2 We demonstrated that siRNA-mediated
knockdown of TRAK2 significantly increases cholesterol efflux from
human macrophage THP-1 cells, highlighting TRAK2 as a potential
pharmacological target which could promote the atheroprotective
pathway of RCT both by upregulating cholesterol removal from mac-
rophages and by increasing HDL biogenesis. Indeed the ability to pro-
mote ABCA1-mediated efflux may be a key determinant of
macrophage cholesterol efflux.25
We have demonstrated that TRAK2 knockdown promotes cho-
lesterol efflux by increasing ABCA1 mRNA and protein levels, which
is supported by several lines of evidence confirming that the effect of
TRAK2 knockdown on efflux is suppressed when ABCA1 expression
is diminished. Although a modest but significant reduction in SCARB1
mRNA was observed, it did not appear to affect the protein abun-
dance of SR-BI and therefore it is unlikely to be relevant. Our data
indicate that TRAK2 knockdown significantly increases LXR-a bind-
ing at the ABCA1 promoter and establishes that TRAK2 regulates
ABCA1 expression by modulating the LXR-mediated transcription of
this gene. LXR agonists increase LXR binding to target promoters by
causing the release of co-repressors.20,21 Therefore, the suppression
of the effect of TRAK2 knockdown on LXR-a binding by LXR agonist
TO901317 suggests that TRAK2 knockdown, like TO901317, may
decrease LXR co-repressor levels at the ABCA1 promoter. The lack
of a decrease in ABCA1 expression when TRAK2 is overexpressed
suggests that TRAK2 may repress LXR by an unknown mechanism.
The role of TRAK2 in LXR co-repressor binding therefore requires
further investigation. LXRs are involved in regulating the expression
of several genes associated with HDL-C metabolism, including
ABCG1.4,5 Further studies are needed to determine the effect of
TRAK2 knockdown on other LXR target genes, towards clarifying
whether the results reflect a general increase in LXR activity or a
ABCA1-specific mechanism. The absence of an effect of TRAK2
knockdown on the expression of LXR-target gene ABCG1, and on
LXRa mRNA levels, suggests that there may be specificity in the acti-
vation of LXR-mediated transcription of ABCA1 by TRAK2.
Figure 6 Summary of key findings. TRAK2 siRNA-mediated knockdown significantly increases LXR-a binding at LXR response elements (LXR RE)
in the ABCA1 promoter, which increases ABCA1 mRNA and protein expression. This leads to an increase in cholesterol efflux to both apoA-I and
isolated HDL particles. Therefore low-TRAK2 levels can promote both HDL biogenesis and RCT.
























































































Cholesterol accumulation in the late endosomal network
enhanced the effect of TRAK2 on ABCA1 expression, with U18666A
treatment doubling the increase in ABCA1 expression elicited by
TRAK2 knockdown. This indicates that the regulation of ABCA1
expression by TRAK2 is sensitive to conditions of intracellular cho-
lesterol accumulation and perturbed efflux, which is consistent with
an effect of TRAK2 knockdown on LXR-mediated ABCA1 transcrip-
tion given the role of LXRs in responding to intracellular cholesterol
content.4 TRAK2 has previously been described as a regulator of
endosomal trafficking,19 however we could not identify any striking
differences in early or late endosomal organization in HepG2 cells
transfected with TRAK2 siRNA relative to controls. Whether
TRAK2’s involvement in LXR-mediated ABCA1 expression and cho-
lesterol efflux is related to its trafficking function is currently
unknown and will be of keen interest to determine.
Here we have not only validated our genetic findings, but we have
also characterized TRAK2 as a novel regulator of LXR-mediated
ABCA1 expression, macrophage cholesterol efflux and hepatic HDL
biogenesis. This study therefore contributes new knowledge about
HDL metabolism and functionality. Current approaches to improve
CVD have focused on the activation of LXRs to increase ABCA1
expression and cholesterol transport, which highlights the potential
for TRAK2 to form part of a therapeutic strategy. Indeed, the nega-
tive correlation between TRAK2 mRNA levels and ABCA1 expression,
cholesterol efflux, and HDL-C concentration makes TRAK2 an
attractive therapeutic target for the treatment of CVD and associated
disorders.
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